IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. More Details
No risks detected for IIN from our risk checks.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has IntriCon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IIN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IIN's weekly volatility (8%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IIN underperformed the US Medical Equipment industry which returned 20.7% over the past year.
Return vs Market: IIN underperformed the US Market which returned 23.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is IntriCon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StShould You Investigate IntriCon Corporation (NASDAQ:IIN) At US$14.87?
9 months ago | Simply Wall StWhat Is IntriCon Corporation's (NASDAQ:IIN) Share Price Doing?
10 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most IntriCon Corporation (NASDAQ:IIN) Stock?
Is IntriCon undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IIN ($20.55) is trading below our estimate of fair value ($50.57)
Significantly Below Fair Value: IIN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IIN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: IIN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IIN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IIN is good value based on its PB Ratio (2.1x) compared to the US Medical Equipment industry average (5.7x).
How is IntriCon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: IIN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IIN's is expected to become profitable in the next 3 years.
Revenue vs Market: IIN's revenue (14% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: IIN's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IIN's Return on Equity is forecast to be high in 3 years time
How has IntriCon performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IIN is currently unprofitable.
Growing Profit Margin: IIN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IIN is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare IIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IIN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: IIN has a negative Return on Equity (-3.16%), as it is currently unprofitable.
How is IntriCon's financial position?
Financial Position Analysis
Short Term Liabilities: IIN's short term assets ($72.6M) exceed its short term liabilities ($18.6M).
Long Term Liabilities: IIN's short term assets ($72.6M) exceed its long term liabilities ($8.4M).
Debt to Equity History and Analysis
Debt Level: IIN is debt free.
Reducing Debt: IIN has no debt compared to 5 years ago when its debt to equity ratio was 39.1%.
Debt Coverage: IIN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IIN has no debt, therefore coverage of interest payments is not a concern.
What is IntriCon current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IIN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IIN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Longval (43 yo)
Mr. J. Scott Longval has been Chief Executive Officer, President and Director of IntriCon Corporation since October 1, 2020. He served as an Executive Vice President at IntriCon Corporation until September...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD439.79K) is below average for companies of similar size in the US market ($USD994.97K).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
|Senior Vice President Operations||no data||US$398.77k||0.70% |
|Senior Vice President of Sales & Marketing||26yrs||US$417.14k||0.24% |
|Chief Human Resource Officer||0.75yr||no data||no data|
|Vice President of Medical Business Development||2yrs||no data||no data|
Experienced Management: IIN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
|Independent Director||20.08yrs||US$146.00k||0.97% |
|Independent Director||1.67yrs||US$108.67k||no data|
|Independent Director||18.92yrs||US$141.00k||0.86% |
|Independent Chairman of the Board||1.67yrs||US$166.33k||0.019% |
|Director Emeritus||4.08yrs||US$104.00k||no data|
|Director||0.83yr||no data||no data|
Experienced Board: IIN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IntriCon Corporation's company bio, employee growth, exchange listings and data sources
- Name: IntriCon Corporation
- Ticker: IIN
- Exchange: NasdaqGM
- Founded: 1930
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$183.786m
- Shares outstanding: 8.94m
- Website: https://www.intricon.com
Number of Employees
- IntriCon Corporation
- 1260 Red Fox Road
- Arden Hills
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IIN||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Jan 1968|
|SLJ||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 1968|
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company oper...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/24 00:15|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.